Edison Investment Research - Euromoney Institutional Investor PLC (ERM) Euromoney Institutional Investor - Awaiting Asset Management resolution

Report

Edison Investment Research

Fiona Orford-Williams

Euromoney Institutional Investor - Awaiting Asset Management resolution

As indicated in the year-end trading update, FY19 figures were ahead of expectations, with continued good progress in Pricing, Data and Market Intelligence (PDMI), where the Fastmarkets brand is gaining traction. There was no new news on Asset Management, now accounted as discontinued. Â£50m of net cash at the year-end allows plenty of scope for investment and M&A towards the goal of a fully â€˜3.0â€™ business model, embedded in its clientsâ€™ workflows. The $20.4m purchase of Wealthâ€“X clearly fits with this. Recent share price weakness has opened up a notable discount to global B2B information peers.

27/11/2019 6 EN

Underlying

Euromoney Institutional Investor PLC

Euromoney Institutional Investors is an international business information group. Co.'s segments are: Asset management, which provides independent research; runs networks and conferences; and provides news and data that are critical for the industry; Pricing, data & market Intelligence, which provides prices, data, analysis and events that are critical for business processes and workflow across a number of industries, such as metals and mining industries, telecoms, insurance, airline and banking; Banking & finance, which provides market intelligence, news, training and conferences; and Commodity events, which consists of conferences in the metals, agriculture and energy sectors.

See profile

GB0006886666 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Fiona Orford-Williams

Other Reports on these Companies

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc 24-Nov-2022 / 12:57 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controlle...

November 24, 2022 November 24, 2022 1 EN

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc 23-Nov-2022 / 13:06 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controlle...

November 23, 2022 November 23, 2022 1 EN

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc 22-Nov-2022 / 14:06 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controlle...

November 22, 2022 November 22, 2022 1 EN

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

2h / 52m 2h / 52m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

3h / 4m 3h / 4m 1 EN

Martyn King

Martyn King

Foxtons Group - FY24 underpinned by market share gains

Foxtons Group’s Q1 revenue grew by 9%, supported by growth in all three divisions as the strategic initiatives continue to gain significant momentum, driven by investment in staff, best-in-class bespoke IT and data platforms. This implies that Foxtons’ medium-term targets are now coming into focus. Market share is being gained in all divisions, which puts Foxtons in a good position as the sales market stabilises. We maintain our valuation of 132p/share and believe that if interest rates stabilise or ease further, there are upside risks to our forecasts.

3h / 22m 3h / 22m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Euromoney Institutional Investor - Awaiting Asset Management resolution

Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc

Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc

Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Foxtons Group - FY24 underpinned by market share gains

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe